ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users

Zhou, Jiandong; Lee, Sharen; Leung, Keith Sai Kit; Wai, Abraham Ka Chung; Liu, Tong; Liu, Ying; Chang, Dong; Wong, Wing Tak; Wong, Ian Chi Kei; Cheung, Bernard Man Yung; Zhang, Qingpeng*; Tse, Gary*厦门大学; 1
ESC Heart Failure2022-4DOI: 10.1002/ehf2.13830
13被引8阅读
引用收藏
分享

摘要

Aims This study aimed to compare the rates of major cardiovascular adverse events in sodium-glucose cotransporter-2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) users in a Chinese population. SGLT2I and DPP4I are increasingly prescribed for type 2 diabetes mellitus patients. However, few population-based studies are comparing their effects on incident heart failure or myocardial infarction. @@@ Methods and results This was a population-based retrospective cohort study using the electronic health record database in Hong Kong, including type 2 diabetes mellitus patients receiving either SGLT2I or DPP4I from 1 January 2015 to 31 December 2020. Propensity score matching was performed in a 1:1 ratio based on demographics, past comorbidities, and non-SGLT2I/DPP4I medications with nearest neighbour matching (caliper = 0.1). Univariable and multivariable Cox models were used to identify significant predictors for new-onset heart failure, new-onset myocardial infarction, cardiovascular mortality, and all-cause mortality. Sensitivity analyses with competing risk models and multiple propensity score matching approaches were conducted. A total of 41 994 patients (58.89% males, median admission age at 58 years old, interquartile range [IQR]: 51.2-65.3) were included with a median follow-up of 5.6 years (IQR: 5.32-5.82). In the matched cohort, SGLT2I use was significantly associated with lower risks of new-onset heart failure (hazard ratio [HR]: 0.73, 95% confidence interval [CI]: [0.66, 0.81], P < 0.0001), myocardial infarction (HR: 0.81, 95% CI: [0.73, 0.90], P < 0.0001), cardiovascular mortality (HR: 0.67, 95% CI: [0.53, 0.84], P < 0.001), and all-cause mortality (HR: 0.26, 95% CI: [0.24, 0.29], P < 0.0001) after adjusting for significant demographics, past comorbidities, and non-SGLT2I/DPP4I medications. @@@ Conclusions SGLT2 inhibitors are protective against adverse cardiovascular events including new-onset heart failure, myocardial infarction, cardiovascular mortality, and all-cause mortality. The prescription of SGLT2I is preferred when taken into consideration individual cardiovascular and metabolic risk profiles in addition to drug-drug interactions.

学科与关键词

关键词
Sodium-glucose co-transporterHeart failureMyocardial infarctionDiabetes mellitus
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
ESC Heart Failure
发表日期
2022-04
卷期
第 9 卷, 第 2 期
页码
1388-1399
DOI
10.1002/ehf2.13830
期刊等级
2区
成果收录
SCIE

作者

  • Z

    Zhou, Jiandong (第一作者)

  • L

    Lee, Sharen

查看全部 12 位作者收起作者
  • L

    Leung, Keith Sai Kit

    univ hong kong

  • W

    Wai, Abraham Ka Chung

    univ hong kong

  • L

    Liu, Tong

    2 · tianjin med univ

  • L

    Liu, Ying

    1 · dalian med univ

  • C

    Chang, Dong

    xiamen univ

  • W

    Wong, Wing Tak

    chinese univ hong kong · cuhk

  • W

    Wong, Ian Chi Kei

    univ hong kong

  • C

    Cheung, Bernard Man Yung

    univ hong kong

  • Z

    Zhang, Qingpeng (通讯)

  • T

    Tse, Gary (通讯)

    2 · tianjin med univ · 1 · dalian med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417